- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Inhibikase Therapeutics GAAP EPS of -$0.10 beats by $0.01 | 1 | Seeking Alpha | ||
| Di | Inhibikase Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 20.10. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.10. | Inhibikase Therapeutics beruft Scott Wasserman in den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| 20.10. | Inhibikase appoints Scott Wasserman to board of directors | 1 | Investing.com | ||
| 13.10. | Chardan initiates Inhibikase Therapeutics stock with neutral rating | 2 | Investing.com | ||
| INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.10. | Chardan startet Coverage für Inhibikase Therapeutics mit neutralem Rating | - | Investing.com Deutsch | ||
| 02.10. | Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 08.09. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.08. | Biotech Stocks At 52-Week Highs - Vogenx, Pharvaris, Solventum, Inhibikase Therapeutics, HeartFlow | 1.339 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 24, 2026, driven by positive results from clinical trials or an upcoming conference participation. Vogenx... ► Artikel lesen | |
| 11.08. | Inhibikase Therapeutics GAAP EPS of -$0.11 in-line | 1 | Seeking Alpha | ||
| 11.08. | Inhibikase Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 11.08. | Inhibikase Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity | 292 | GlobeNewswire (Europe) | WILMINGTON, Del., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily... ► Artikel lesen | |
| 23.07. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 23.07. | Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH | 427 | GlobeNewswire (Europe) | WILMINGTON, Del., July 23, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary... ► Artikel lesen | |
| 15.07. | Biotech Stocks Hit 52-Week Highs - The Oncology Institute, Inhibikase Therapeutics, Alto Neuroscience, Elevance Health, Privia Health | 1.003 | AFX News | WASHINGTON (dpa-AFX) - These biotech stocks touched a 52-week high on July 14, 2026, attributable to key catalysts like announced offerings to increase capital and the expansion of business... ► Artikel lesen | |
| 14.07. | Inhibikase sells $50M of common stock to RA Capital | 1 | Seeking Alpha | ||
| 14.07. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.07. | Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility | 416 | GlobeNewswire (Europe) | WILMINGTON, Del., July 14, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 262,20 | -0,42 % | Eli Lilly kauft AtaiBeckley für 2,8 Milliarden Dollar - wer behandelt künftig die Patienten? | ||
| TEVA PHARMACEUTICAL INDUSTRIES | 42,580 | +0,45 % | Tourette ist mehr als sichtbare Tics: Teva und Neurothera verfolgen neue Behandlungsansätze | ||
| EYEPOINT | 0,380 | +4,97 % | EyePoint Pharmaceuticals GAAP EPS of -$1.07 misses by $0.15, revenue of $0.8M beats by $0.57M | ||
| ORGANIGRAM GLOBAL | 0,763 | -0,26 % | Organigram: Aurora Cannabis Acquisition Valued At C$561 Million To Create Global Cannabis Platform | ||
| QUANTUM BIOPHARMA | 1,781 | +5,26 % | Quantum Biopharma Ltd: Quantum Biopharma shareholders approve AGM resolutions | ||
| ASSEMBLY BIOSCIENCES | 18,760 | -1,78 % | Assembly Biosciences: Phase 2 läuft - was jetzt wichtig wird | ||
| NEKTAR THERAPEUTICS | 33,230 | -1,80 % | Nektar Therapeutics: New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 | Rezpegaldesleukindemonstrateddurabilityanddeepeningofresponsethroughone year of treatment in two dermatological indications, reinforcing the differentiated properties... ► Artikel lesen | |
| AMARIN | 10,300 | +0,98 % | Amarin presents cardiovascular research data at AHA meeting | ||
| FILANA THERAPEUTICS | 0,461 | +5,74 % | FILANA THERAPEUTICS, INC. - 8-K, Current Report | ||
| COMPASS PATHWAYS | 8,350 | +0,60 % | Compass Pathfinder Limited: Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th | Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Jefferies... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 220,20 | +0,14 % | Bernstein cuts Jazz Pharmaceuticals stock price target on Zepzelca outlook | ||
| ALTIMMUNE | 1,750 | +0,92 % | Altimmune, Inc: Altimmune Announces Third Quarter 2026 Financial Results and Business Update | ||
| ACHIEVE LIFE SCIENCES | 5,750 | 0,00 % | ACHIEVE LIFE SCIENCES, INC. - 10-Q, Quarterly Report | ||
| SELLAS LIFE SCIENCES | 7,480 | -0,27 % | Sellas Life Sciences Group: Regal-Studie erreicht die nächste Marke, aber die Aktie fällt - vor der Schlussanalyse | ||
| MADRIGAL PHARMACEUTICALS | 387,40 | -0,08 % | Madrigal Pharmaceuticals: H.C. Wainwright bekräftigt Kaufempfehlung gestützt auf starke Marktposition |
INHIBIKASE THERAPEUTICS INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von +0,020 (+1,29 %) liegt der Kurs bei 1,570 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBIKASE THERAPEUTICS INC finden Sie auf Wallstreet Online.